Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for rare neuromuscular and cardiomyopathy diseases. Its pipeline is centered on small-molecule drug candidates such as sevasemten and EDG-7500, which are being advanced through Phase 2 trials and preclinical development.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueClinical-stage small-molecule therapy for rare neuromuscular diseases, including Becker and other muscular dystrophies.
Clinical-stage candidate being developed for hypertrophic cardiomyopathy.
Earlier-stage cardiometabolic programs, including EDG-003 and additional candidates.
Internal platform used to identify and optimize small-molecule precision medicines.
Customers
Edgewise does not yet sell approved products; its current 'customers' are clinical trial participants, investigators, CROs, CDMOs, and regulators that enable development. If approved, its commercial buyers would be specialty physicians, hospitals, and payors covering rare-disease and cardiology therapies in the U.S. and select international markets.
Patients with Becker, Duchenne and related muscular dystrophies who would use sevasemten if approved.
Patients with HCM targeted by EDG-7500 clinical development and eventual commercialization.
Investigators, CROs and sites that execute the company's Phase 2 studies and generate development data.
Third-party manufacturers that supply active ingredient and fill-finish services for preclinical and clinical material.
Government and commercial payors, plus specialists, that would determine access and uptake after approval.
Strategy
Edgewise is prioritizing advancement of sevasemten and EDG-7500 through Phase 2 development while building the data package needed for regulatory discussions and future commercialization. It is also expanding its discovery platform and operational infrastructure so it can support later-stage trials, manufacturing redundancy, and eventual market launch.
Clinical data in Becker and other muscular dystrophies is central to regulatory and partnering value.
Diversifies the pipeline into cardiology and broadens the company's future commercial opportunity.
Rare-disease drugs depend on payer coverage and pricing discipline to be commercially viable.
Additional candidates and redundant supply reduce single-asset and single-source risk.
Geography
Edgewise is headquartered in Boulder, Colorado and currently conducts development primarily in the United States. Management says any approved products would be marketed in the U.S. and select international markets, which makes future reimbursement and pricing exposure meaningfully global even though the company is still pre-commercial.
Risks
Edgewise is a pre-revenue clinical-stage company, so its value depends heavily on successful trial outcomes, regulatory approval, and future reimbursement. It also relies on third-party CROs and CDMOs for development and manufacturing, which creates execution and supply-chain risk, while rare-disease pricing and payor coverage could limit commercialization even if approval is achieved.
- Clinical development failureImpact: CriticalLikelihood: Medium
Sevasemten and EDG-7500 are still in Phase 2, and efficacy or safety issues could halt programs.
Exposure: Multiple ongoing Phase 2 trials in rare diseases
- Capital needs and dilutionImpact: HighLikelihood: High
As a pre-revenue biotech, continued R&D and trial expansion may require additional financing.
Exposure: Ongoing clinical and preclinical programs
- Regulatory approval uncertaintyImpact: HighLikelihood: Medium
FDA and ex-U.S. regulators may require additional data or reject applications for rare-disease indications.
Exposure - Reimbursement and pricing riskImpact: HighLikelihood: Medium
Small patient populations require high per-patient pricing, but payors may restrict coverage or reimbursement levels.
Exposure: U.S. and international commercialization
- Third-party manufacturing dependenceImpact: HighLikelihood: Medium
The company uses CDMOs on purchase-order terms and lacks redundant supply arrangements today.
Exposure
Accounting
Judgemental itemsManagement estimates services performed by CROs, investigators and CDMOs before invoices are received.
Impact: Can shift expenses between periods and affect operating loss comparability
Milestone-based contracts and protocol changes alter the timing of recognized costs.
Impact: Quarterly R&D expense volatility
Equity awards are used to attract and retain scientific and corporate talent.
Impact: Raises operating expenses without immediate cash outflow
As a pre-revenue company, cash runway and financing assumptions are central to disclosures.
Impact: Affects investor view of dilution and funding risk
Similar listed companies
Publicly listed companies with a comparable business focus.
PepGen Inc.
PEPG · Pharmaceutical Preparations
Vistagen Therapeutics, Inc.
VTGN · Pharmaceutical Preparations
Vistagen Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on neuroscience disorders.
Solid Biosciences Inc.
SLDB · Biological Products, (No Diagnostic Substances)
enGene Therapeutics Inc.
ENGN · Biological Products, (No Diagnostic Substances)
Odyssey Health, Inc.
ODYY · Surgical & Medical Instruments & Apparatus
Lexeo Therapeutics, Inc.
LXEO · Biological Products, (No Diagnostic Substances)
Lexeo Therapeutics is a U.S.-based clinical-stage biotechnology company developing gene therapy candidates for serious cardiovascular and neuromuscular diseases.
Last updated: 24/09/2026